Comparative clinical study of 7432-S (ceftibuten) and cefaclor in chronic respiratory tract infections by A double-blind study

Masaru Nasu; Akira Saitoh; Kohtaro Ohizumi; Izumi Hayashi; Hiroyuki Kobayashi; Kohya Shiba; Shigeki Odagiri; Fumio Miki; Yoshihito Niki; Atsushi Saitoh; Akira Saitoh; Masumi Tomizawa; Ichiro Nakayama; Yohmei Hiraga; Kazuo Takebe; Katsuhiro Okamoto; Morio Sagara; Kiuoshi Konno; Kohtaro Ohizumi; Akira Watanabe; Seiichi Aonuma; Tamotus Takishima; Shiroh Ida; Izumi Hayashi; Kikuo Ohnuma; Masaaki Arakawa; Kohichi Wada; Hidetsugu Higuchi; Osamu Sekine; Nobuki Aoki; Masataka Katsh; Tsuguzi Okui; Toshio Fukui; Toshito Tohgoh; Takanori Fujita; Atsushi Azisawa; Ken Kawai; Otohiko Kunii; Yasuo Ono; Hajime Nishiya; Tsukoh Ohtani; Toshiaki Haga; Syuichi Sawamoto; Yoshio Uzuka; Atsushi Saitoh; Jingoro Shimada; Kohya Shiba; Kihachiro Shimizu; Teppei Kumada; Junichi Katahira; Tomoko Fukada; Hiroyuki Kobayashi; Shin Kawai; Hiroshi Oshitani; Tatsuo Katoh; Hideo Mogami; Kaoru Shimada; Yasuyuki Sano; Yasufumi Miyamoto; Takashi Inamatsu; Makiko Fukavama; Junzaburo Kabe; Kohichiro Kudo; Hideo Ikemoto; Kazuyoshi Watanabe; Tsuneo Hamamoto; Mayumi Takahashi; Hiroichi Tanimoto; Yoshitaka Nakamori; Nadhiko Chonabayashi; Tatsuo Nakatani; Takao Ohkubo; Akira Itoh; Hirotada Ikeda; Masanori Matsumura; Masanori Ri; Takaaki Miwa; Shigeki Qdagiri; Kaneo Suzuki; Kou Murohashi; Hiroshi Takahashi; Hiroyuki Numata; Yuuji Watanuki; Kaoru Ohyama; Fumio Miki; Rinzoh Soejima; Yoshihito Niki; Yoshihisa Nakagawa; Yoshiro Sawae; Yukio Kumagai; Hozumi Yamada; Osamu Katoh; Kohei Hara; Masaki Hirota; Keizo Yamaguchi; Sigeru Kohno; Yasumasa Doutsij; Akira Yasuoka; Kazuo Sasayama; Hiroshi Yamada; Toshiaki Hayashi; Yoichi Inoue; Masafumi Hayashida; Keizoh Matsumoto; Harumi Shishido; Tsuyoshi Nagatake; Masakazu Takasugi; Yoshiaki Utsunomiya; Masaru Nasu; Hideaki Shigeno; Jun Gotoh; Takayoshi Tashiro; Atsushi Saitoh; Yoshiteru Shigeno; Tsuyoshi Ueiiara; Yuei Irabu; Mitsuyoshi Nakashima

doi:10.11250/chemotherapy1953.37.Supplement1_619

Comparative clinical study of 7432-S (ceftibuten) and cefaclor in chronic respiratory tract infections by A double-blind study

Masaru Nasu, Akira Saitoh, Kohtaro Ohizumi, Izumi Hayashi, Hiroyuki Kobayashi, Kohya Shiba, Shigeki Odagiri, Fumio Miki, Yoshihito Niki, Atsushi Saitoh, Akira Saitoh, Masumi Tomizawa, Ichiro Nakayama, Yohmei Hiraga, Kazuo Takebe, Katsuhiro Okamoto, Morio Sagara, Kiuoshi Konno, Kohtaro Ohizumi, Akira WatanabeSeiichi Aonuma, Tamotus Takishima, Shiroh Ida, Izumi Hayashi, Kikuo Ohnuma, Masaaki Arakawa, Kohichi Wada, Hidetsugu Higuchi, Osamu Sekine, Nobuki Aoki, Masataka Katsh, Tsuguzi Okui, Toshio Fukui, Toshito Tohgoh, Takanori Fujita, Atsushi Azisawa, Ken Kawai, Otohiko Kunii, Yasuo Ono, Hajime Nishiya, Tsukoh Ohtani, Toshiaki Haga, Syuichi Sawamoto, Yoshio Uzuka, Atsushi Saitoh, Jingoro Shimada, Kohya Shiba, Kihachiro Shimizu, Teppei Kumada, Junichi Katahira, Tomoko Fukada, Hiroyuki Kobayashi, Shin Kawai, Hiroshi Oshitani, Tatsuo Katoh, Hideo Mogami, Kaoru Shimada, Yasuyuki Sano, Yasufumi Miyamoto, Takashi Inamatsu, Makiko Fukavama, Junzaburo Kabe, Kohichiro Kudo, Hideo Ikemoto, Kazuyoshi Watanabe, Tsuneo Hamamoto, Mayumi Takahashi, Hiroichi Tanimoto, Yoshitaka Nakamori, Nadhiko Chonabayashi, Tatsuo Nakatani, Takao Ohkubo, Akira Itoh, Hirotada Ikeda, Masanori Matsumura, Masanori Ri, Takaaki Miwa, Shigeki Qdagiri, Kaneo Suzuki, Kou Murohashi, Hiroshi Takahashi, Hiroyuki Numata, Yuuji Watanuki, Kaoru Ohyama, Fumio Miki, Rinzoh Soejima, Yoshihito Niki, Yoshihisa Nakagawa, Yoshiro Sawae, Yukio Kumagai, Hozumi Yamada, Osamu Katoh, Kohei Hara, Masaki Hirota, Keizo Yamaguchi, Sigeru Kohno, Yasumasa Doutsij, Akira Yasuoka, Kazuo Sasayama, Hiroshi Yamada, Toshiaki Hayashi, Yoichi Inoue, Masafumi Hayashida, Keizoh Matsumoto, Harumi Shishido, Tsuyoshi Nagatake, Masakazu Takasugi, Yoshiaki Utsunomiya, Masaru Nasu, Hideaki Shigeno, Jun Gotoh, Takayoshi Tashiro, Atsushi Saitoh, Yoshiteru Shigeno, Tsuyoshi Ueiiara, Yuei Irabu, Mitsuyoshi Nakashima

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

We conducted a comparative double-blind study of 7432-s (ceftibuten), a new oral cephem antibiotic, and cefaclor (CCL) to evaluate the efficacy, safety and usefulness of both drugs in the treatment of chronic respiratory tract infections. 7432-S was given orally at a daily dosage of 400 mg, and CCL at a daily dosage of 1500 mg for 14 days. The following results were obtained: 1) Of the total 170 patiens (85 in the 7432-S group, 85 in the CCL group), 145 were evaluated for efficacy by the committee members (71 in the 7432-S group, 74 in the CCL group). No significant differrence was noted between the two drug groups with respect to the exclusion/dropout percentage, or patient background. 2) The clinical efficacy rate judged by the committee members was 71.8% for the 7432-S group and 71.6 % for the CCL group, with no significant difference between the two drug groups. Nor was any significant difference noted between the two drug groups in the response rate as judged by the physicians. Bacteriologically, the elimination rate was 76.9% (30/39 strains) for the 7432-S group and 64.7% (22/34 strains) for the CCL group, with no significant difference between the groups. 3) As for the incidence of adverse reactions or abnormal labaratory findings, there was also no significant difference between the groups. 4) The usefulness rate judged by the committee members was 67.1% for the 7432-S group and 68.0% for the CCL group, with no significant difference between the groups. Nor was any significant difference noted in the evaluation of usefulness as judged by the physicians. These results demonstrated that 7432-S administered at a daily dosage of 400 mg (in two divided portions) was as useful as CCL at a daily dosage of 1500 mg (in three divided portions) in the treatment of chronic respiratory tract infections.

Original language	English
Pages (from-to)	619-643
Number of pages	25
Journal	Chemotherapy
Volume	37
DOIs	https://doi.org/10.11250/chemotherapy1953.37.Supplement1_619
Publication status	Published - 1989
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.37.Supplement1_619

Cite this

Nasu, M., Saitoh, A., Ohizumi, K., Hayashi, I., Kobayashi, H., Shiba, K., Odagiri, S., Miki, F., Niki, Y., Saitoh, A., Saitoh, A., Tomizawa, M., Nakayama, I., Hiraga, Y., Takebe, K., Okamoto, K., Sagara, M., Konno, K., Ohizumi, K., ... Nakashima, M. (1989). Comparative clinical study of 7432-S (ceftibuten) and cefaclor in chronic respiratory tract infections by A double-blind study. Chemotherapy, 37, 619-643. https://doi.org/10.11250/chemotherapy1953.37.Supplement1_619

Nasu, M, Saitoh, A, Ohizumi, K, Hayashi, I, Kobayashi, H, Shiba, K, Odagiri, S, Miki, F, Niki, Y, Saitoh, A, Saitoh, A, Tomizawa, M, Nakayama, I, Hiraga, Y, Takebe, K, Okamoto, K, Sagara, M, Konno, K, Ohizumi, K, Watanabe, A, Aonuma, S, Takishima, T, Ida, S, Hayashi, I, Ohnuma, K, Arakawa, M, Wada, K, Higuchi, H, Sekine, O, Aoki, N, Katsh, M, Okui, T, Fukui, T, Tohgoh, T, Fujita, T, Azisawa, A, Kawai, K, Kunii, O, Ono, Y, Nishiya, H, Ohtani, T, Haga, T, Sawamoto, S, Uzuka, Y, Saitoh, A, Shimada, J, Shiba, K, Shimizu, K, Kumada, T, Katahira, J, Fukada, T, Kobayashi, H, Kawai, S, Oshitani, H, Katoh, T, Mogami, H, Shimada, K, Sano, Y, Miyamoto, Y, Inamatsu, T, Fukavama, M, Kabe, J, Kudo, K, Ikemoto, H, Watanabe, K, Hamamoto, T, Takahashi, M, Tanimoto, H, Nakamori, Y, Chonabayashi, N, Nakatani, T, Ohkubo, T, Itoh, A, Ikeda, H, Matsumura, M, Ri, M, Miwa, T, Qdagiri, S, Suzuki, K, Murohashi, K, Takahashi, H, Numata, H, Watanuki, Y, Ohyama, K, Miki, F, Soejima, R, Niki, Y, Nakagawa, Y, Sawae, Y, Kumagai, Y, Yamada, H, Katoh, O, Hara, K, Hirota, M, Yamaguchi, K, Kohno, S, Doutsij, Y, Yasuoka, A, Sasayama, K, Yamada, H, Hayashi, T, Inoue, Y, Hayashida, M, Matsumoto, K, Shishido, H, Nagatake, T, Takasugi, M, Utsunomiya, Y, Nasu, M, Shigeno, H, Gotoh, J, Tashiro, T, Saitoh, A, Shigeno, Y, Ueiiara, T, Irabu, Y & Nakashima, M 1989, 'Comparative clinical study of 7432-S (ceftibuten) and cefaclor in chronic respiratory tract infections by A double-blind study', Chemotherapy, vol. 37, pp. 619-643. https://doi.org/10.11250/chemotherapy1953.37.Supplement1_619

@article{90910b6c344e4ce4aefddcafba74538d,

title = "Comparative clinical study of 7432-S (ceftibuten) and cefaclor in chronic respiratory tract infections by A double-blind study",

abstract = "We conducted a comparative double-blind study of 7432-s (ceftibuten), a new oral cephem antibiotic, and cefaclor (CCL) to evaluate the efficacy, safety and usefulness of both drugs in the treatment of chronic respiratory tract infections. 7432-S was given orally at a daily dosage of 400 mg, and CCL at a daily dosage of 1500 mg for 14 days. The following results were obtained: 1) Of the total 170 patiens (85 in the 7432-S group, 85 in the CCL group), 145 were evaluated for efficacy by the committee members (71 in the 7432-S group, 74 in the CCL group). No significant differrence was noted between the two drug groups with respect to the exclusion/dropout percentage, or patient background. 2) The clinical efficacy rate judged by the committee members was 71.8% for the 7432-S group and 71.6 % for the CCL group, with no significant difference between the two drug groups. Nor was any significant difference noted between the two drug groups in the response rate as judged by the physicians. Bacteriologically, the elimination rate was 76.9% (30/39 strains) for the 7432-S group and 64.7% (22/34 strains) for the CCL group, with no significant difference between the groups. 3) As for the incidence of adverse reactions or abnormal labaratory findings, there was also no significant difference between the groups. 4) The usefulness rate judged by the committee members was 67.1% for the 7432-S group and 68.0% for the CCL group, with no significant difference between the groups. Nor was any significant difference noted in the evaluation of usefulness as judged by the physicians. These results demonstrated that 7432-S administered at a daily dosage of 400 mg (in two divided portions) was as useful as CCL at a daily dosage of 1500 mg (in three divided portions) in the treatment of chronic respiratory tract infections.",

author = "Masaru Nasu and Akira Saitoh and Kohtaro Ohizumi and Izumi Hayashi and Hiroyuki Kobayashi and Kohya Shiba and Shigeki Odagiri and Fumio Miki and Yoshihito Niki and Atsushi Saitoh and Akira Saitoh and Masumi Tomizawa and Ichiro Nakayama and Yohmei Hiraga and Kazuo Takebe and Katsuhiro Okamoto and Morio Sagara and Kiuoshi Konno and Kohtaro Ohizumi and Akira Watanabe and Seiichi Aonuma and Tamotus Takishima and Shiroh Ida and Izumi Hayashi and Kikuo Ohnuma and Masaaki Arakawa and Kohichi Wada and Hidetsugu Higuchi and Osamu Sekine and Nobuki Aoki and Masataka Katsh and Tsuguzi Okui and Toshio Fukui and Toshito Tohgoh and Takanori Fujita and Atsushi Azisawa and Ken Kawai and Otohiko Kunii and Yasuo Ono and Hajime Nishiya and Tsukoh Ohtani and Toshiaki Haga and Syuichi Sawamoto and Yoshio Uzuka and Atsushi Saitoh and Jingoro Shimada and Kohya Shiba and Kihachiro Shimizu and Teppei Kumada and Junichi Katahira and Tomoko Fukada and Hiroyuki Kobayashi and Shin Kawai and Hiroshi Oshitani and Tatsuo Katoh and Hideo Mogami and Kaoru Shimada and Yasuyuki Sano and Yasufumi Miyamoto and Takashi Inamatsu and Makiko Fukavama and Junzaburo Kabe and Kohichiro Kudo and Hideo Ikemoto and Kazuyoshi Watanabe and Tsuneo Hamamoto and Mayumi Takahashi and Hiroichi Tanimoto and Yoshitaka Nakamori and Nadhiko Chonabayashi and Tatsuo Nakatani and Takao Ohkubo and Akira Itoh and Hirotada Ikeda and Masanori Matsumura and Masanori Ri and Takaaki Miwa and Shigeki Qdagiri and Kaneo Suzuki and Kou Murohashi and Hiroshi Takahashi and Hiroyuki Numata and Yuuji Watanuki and Kaoru Ohyama and Fumio Miki and Rinzoh Soejima and Yoshihito Niki and Yoshihisa Nakagawa and Yoshiro Sawae and Yukio Kumagai and Hozumi Yamada and Osamu Katoh and Kohei Hara and Masaki Hirota and Keizo Yamaguchi and Sigeru Kohno and Yasumasa Doutsij and Akira Yasuoka and Kazuo Sasayama and Hiroshi Yamada and Toshiaki Hayashi and Yoichi Inoue and Masafumi Hayashida and Keizoh Matsumoto and Harumi Shishido and Tsuyoshi Nagatake and Masakazu Takasugi and Yoshiaki Utsunomiya and Masaru Nasu and Hideaki Shigeno and Jun Gotoh and Takayoshi Tashiro and Atsushi Saitoh and Yoshiteru Shigeno and Tsuyoshi Ueiiara and Yuei Irabu and Mitsuyoshi Nakashima",

year = "1989",

doi = "10.11250/chemotherapy1953.37.Supplement1_619",

language = "English",

volume = "37",

pages = "619--643",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Comparative clinical study of 7432-S (ceftibuten) and cefaclor in chronic respiratory tract infections by A double-blind study

AU - Nasu, Masaru

AU - Saitoh, Akira

AU - Ohizumi, Kohtaro

AU - Hayashi, Izumi

AU - Kobayashi, Hiroyuki

AU - Shiba, Kohya

AU - Odagiri, Shigeki

AU - Miki, Fumio

AU - Niki, Yoshihito

AU - Saitoh, Atsushi

AU - Saitoh, Akira

AU - Tomizawa, Masumi

AU - Nakayama, Ichiro

AU - Hiraga, Yohmei

AU - Takebe, Kazuo

AU - Okamoto, Katsuhiro

AU - Sagara, Morio

AU - Konno, Kiuoshi

AU - Ohizumi, Kohtaro

AU - Watanabe, Akira

AU - Aonuma, Seiichi

AU - Takishima, Tamotus

AU - Ida, Shiroh

AU - Hayashi, Izumi

AU - Ohnuma, Kikuo

AU - Arakawa, Masaaki

AU - Wada, Kohichi

AU - Higuchi, Hidetsugu

AU - Sekine, Osamu

AU - Aoki, Nobuki

AU - Katsh, Masataka

AU - Okui, Tsuguzi

AU - Fukui, Toshio

AU - Tohgoh, Toshito

AU - Fujita, Takanori

AU - Azisawa, Atsushi

AU - Kawai, Ken

AU - Kunii, Otohiko

AU - Ono, Yasuo

AU - Nishiya, Hajime

AU - Ohtani, Tsukoh

AU - Haga, Toshiaki

AU - Sawamoto, Syuichi

AU - Uzuka, Yoshio

AU - Saitoh, Atsushi

AU - Shimada, Jingoro

AU - Shiba, Kohya

AU - Shimizu, Kihachiro

AU - Kumada, Teppei

AU - Katahira, Junichi

AU - Fukada, Tomoko

AU - Kobayashi, Hiroyuki

AU - Kawai, Shin

AU - Oshitani, Hiroshi

AU - Katoh, Tatsuo

AU - Mogami, Hideo

AU - Shimada, Kaoru

AU - Sano, Yasuyuki

AU - Miyamoto, Yasufumi

AU - Inamatsu, Takashi

AU - Fukavama, Makiko

AU - Kabe, Junzaburo

AU - Kudo, Kohichiro

AU - Ikemoto, Hideo

AU - Watanabe, Kazuyoshi

AU - Hamamoto, Tsuneo

AU - Takahashi, Mayumi

AU - Tanimoto, Hiroichi

AU - Nakamori, Yoshitaka

AU - Chonabayashi, Nadhiko

AU - Nakatani, Tatsuo

AU - Ohkubo, Takao

AU - Itoh, Akira

AU - Ikeda, Hirotada

AU - Matsumura, Masanori

AU - Ri, Masanori

AU - Miwa, Takaaki

AU - Qdagiri, Shigeki

AU - Suzuki, Kaneo

AU - Murohashi, Kou

AU - Takahashi, Hiroshi

AU - Numata, Hiroyuki

AU - Watanuki, Yuuji

AU - Ohyama, Kaoru

AU - Miki, Fumio

AU - Soejima, Rinzoh

AU - Niki, Yoshihito

AU - Nakagawa, Yoshihisa

AU - Sawae, Yoshiro

AU - Kumagai, Yukio

AU - Yamada, Hozumi

AU - Katoh, Osamu

AU - Hara, Kohei

AU - Hirota, Masaki

AU - Yamaguchi, Keizo

AU - Kohno, Sigeru

AU - Doutsij, Yasumasa

AU - Yasuoka, Akira

AU - Sasayama, Kazuo

AU - Yamada, Hiroshi

AU - Hayashi, Toshiaki

AU - Inoue, Yoichi

AU - Hayashida, Masafumi

AU - Matsumoto, Keizoh

AU - Shishido, Harumi

AU - Nagatake, Tsuyoshi

AU - Takasugi, Masakazu

AU - Utsunomiya, Yoshiaki

AU - Nasu, Masaru

AU - Shigeno, Hideaki

AU - Gotoh, Jun

AU - Tashiro, Takayoshi

AU - Saitoh, Atsushi

AU - Shigeno, Yoshiteru

AU - Ueiiara, Tsuyoshi

AU - Irabu, Yuei

AU - Nakashima, Mitsuyoshi

PY - 1989

Y1 - 1989

N2 - We conducted a comparative double-blind study of 7432-s (ceftibuten), a new oral cephem antibiotic, and cefaclor (CCL) to evaluate the efficacy, safety and usefulness of both drugs in the treatment of chronic respiratory tract infections. 7432-S was given orally at a daily dosage of 400 mg, and CCL at a daily dosage of 1500 mg for 14 days. The following results were obtained: 1) Of the total 170 patiens (85 in the 7432-S group, 85 in the CCL group), 145 were evaluated for efficacy by the committee members (71 in the 7432-S group, 74 in the CCL group). No significant differrence was noted between the two drug groups with respect to the exclusion/dropout percentage, or patient background. 2) The clinical efficacy rate judged by the committee members was 71.8% for the 7432-S group and 71.6 % for the CCL group, with no significant difference between the two drug groups. Nor was any significant difference noted between the two drug groups in the response rate as judged by the physicians. Bacteriologically, the elimination rate was 76.9% (30/39 strains) for the 7432-S group and 64.7% (22/34 strains) for the CCL group, with no significant difference between the groups. 3) As for the incidence of adverse reactions or abnormal labaratory findings, there was also no significant difference between the groups. 4) The usefulness rate judged by the committee members was 67.1% for the 7432-S group and 68.0% for the CCL group, with no significant difference between the groups. Nor was any significant difference noted in the evaluation of usefulness as judged by the physicians. These results demonstrated that 7432-S administered at a daily dosage of 400 mg (in two divided portions) was as useful as CCL at a daily dosage of 1500 mg (in three divided portions) in the treatment of chronic respiratory tract infections.

AB - We conducted a comparative double-blind study of 7432-s (ceftibuten), a new oral cephem antibiotic, and cefaclor (CCL) to evaluate the efficacy, safety and usefulness of both drugs in the treatment of chronic respiratory tract infections. 7432-S was given orally at a daily dosage of 400 mg, and CCL at a daily dosage of 1500 mg for 14 days. The following results were obtained: 1) Of the total 170 patiens (85 in the 7432-S group, 85 in the CCL group), 145 were evaluated for efficacy by the committee members (71 in the 7432-S group, 74 in the CCL group). No significant differrence was noted between the two drug groups with respect to the exclusion/dropout percentage, or patient background. 2) The clinical efficacy rate judged by the committee members was 71.8% for the 7432-S group and 71.6 % for the CCL group, with no significant difference between the two drug groups. Nor was any significant difference noted between the two drug groups in the response rate as judged by the physicians. Bacteriologically, the elimination rate was 76.9% (30/39 strains) for the 7432-S group and 64.7% (22/34 strains) for the CCL group, with no significant difference between the groups. 3) As for the incidence of adverse reactions or abnormal labaratory findings, there was also no significant difference between the groups. 4) The usefulness rate judged by the committee members was 67.1% for the 7432-S group and 68.0% for the CCL group, with no significant difference between the groups. Nor was any significant difference noted in the evaluation of usefulness as judged by the physicians. These results demonstrated that 7432-S administered at a daily dosage of 400 mg (in two divided portions) was as useful as CCL at a daily dosage of 1500 mg (in three divided portions) in the treatment of chronic respiratory tract infections.

UR - http://www.scopus.com/inward/record.url?scp=0024811690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024811690&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.37.Supplement1_619

DO - 10.11250/chemotherapy1953.37.Supplement1_619

M3 - Article

AN - SCOPUS:0024811690

SN - 0009-3165

VL - 37

SP - 619

EP - 643

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

ER -

Comparative clinical study of 7432-S (ceftibuten) and cefaclor in chronic respiratory tract infections by A double-blind study

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this